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ABSTRACT
The diffusely infiltrative nature of glioblastoma (GBM) makes them highly
recurrent. IGF2 mRNA-binding protein 3 (IMP3), a GBM upregulated RNA binding
protein, promotes glioma cell migration. An integrative bioinformatics analysis
identified p65 (RELA), a subunit of NF-κB heterodimer as a target and an important
mediator of IMP3 promoted glioma cell migration. IMP3 increased p65 protein levels
without any change in p65 transcript levels, but promoted its polysome association. RIPPCR demonstrated the binding of IMP3 to p65 transcript. UV crosslinking experiments
with in vitro transcribed RNA confirmed the specific and direct binding of IMP3 to
sites on p65 3′UTR. Further, IMP3 induced luciferase activity from p65 3′UTR reporter
carrying wild type sites but not mutated sites. Exogenous overexpression of p65 from
a 3′UTR-less construct rescued the reduced migration of glioma cells in IMP3 silenced
condition. In addition, IMP3 silencing inhibited glioma stem-like cell maintenance and
migration. The exogenous overexpression of 3′UTR-less p65 significantly alleviated the
inhibition of neurosphere formation observed in IMP3 silenced glioma stem-like cells.
Further, we show that IMP3 is transcriptionally activated by NF-κB pathway indicating
the presence of a positive feedback loop between IMP3 and p65. This study establishes
p65 as a novel target of IMP3 in increasing glioma cell migration and underscores the
significance of IMP3-p65 feedback loop for therapeutic targeting in GBM.

INTRODUCTION

contribute to this heterogeneity and the belligerence of the
disease [3–5] . They have been demonstrated to be resistant
to the current treatment modalities and are ascertained to
be the culprits for the high rates of GBM recurrence [4].
They have also been shown to have high migratory capacity
[5]. Thus, the identification of molecules contributing to
migratory potential of glioma cells and in GSC maintenance
will help in adding lucrative potential targets for adjuvant
therapies. Inhibition of such molecules will diminish the
tumor load and resistance to existing therapies which may
result in lower recurrence rate.

Glioblastoma (GBM) is one of the leading causes
of death caused due to brain tumors. Despite the technical
advances in diagnostics and the present treatment modalities
the median overall survival of the patients remains 14.6
months [1, 2]. Malignant and heterogeneous nature of
the GBM tumors contribute to the observed resistance
and recurrence [3]. In the recent past, many authors have
demonstrated the existence of a small population of glioma
stem-like cells (GSCs) in the tumors which in multiple ways
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Increasing evidence establishes the role of RNA
binding proteins in regulating RNA splicing, stability,
localization, modifications and translation [6, 7]. While,
recent evidence associates derailed expression or activity
of these RBPs with several genetic diseases including
cancer, their cellular target repertoire, how they regulate
the transcriptome and proteome and whether they can
be used for therapeutic intervention warrants further
investigation [8–11]. IMP3 is an example of an oncofetal
RNA binding protein, which has been associated with
various malignancies [12–16]. Few of the bonafide targets
of the protein are emerging from the recent research [9].
In this study, we have identified p65 (RelA) as a mediator
of IMP3 functions including migration of glioma cell
lines and maintenance of GSCs. IMP3 binds to 3′UTR
of p65 transcript and enhances its translation. p65 is a
subunit of NF-κB transcription factor and this increase in
translation of protein also resulted in a higher activity of
the NF-κB pathway. Moreover, we demonstrate IMP3 to
be a transcriptional target of p65. We have thus, delineated
IMP3- NF-κB cascade by which IMP3 contributes in
migration of glioma bulk and stem-like cells.

member of NF-κB heterodimeric transcription factor
complex [21]. NF-κB pathway has been extensively
associated with aggressive phenotypes of GBM, especially
migration, invasion, angiogenesis, chemo-resistance and
GSC maintenance [22–24].
NF-κB primarily exists as a heterodimeric
transcription factor consisting of p65 and p50 subunits
[21]. To experimentally demonstrate that p65 is a target of
IMP3, we measured the p65-dependent luciferase activity
in glioma cells after modulating IMP3 levels. Exogenous
overexpression of IMP3 in LN229 glioma cells increased
luciferase activity in a concentration dependent manner,
while knockdown of IMP3 in U87, T98G and U138
cells led to a significant reduction in the activity from
NF-κB dependent reporter (Figure 1B and 1C). Next, we
assessed the role of p65 as a downstream effector of IMP3
mediated migration. As expected, we observed a reduced
migratory capacity of U138 cells upon IMP3 knockdown
(Figure 1D and 1E; compare bar 1 with 2). Exogenous
overexpression of p65 alleviated the diminished
migration observed in IMP3 silenced U138 cells
(Figure 1D and 1E; compare bar 4 with 2). Silencing of
IMP3 and overexpression of p65 was confirmed using
western blot (Figure 1F). Collectively, these results
establish p65 as a target of IMP3 in mediating its promigratory functions in glioma cells.

RESULTS
Identification of RELA/p65 as an IMP3 target in
promoting glioma cell migration

IMP3 activates NF-κB activity by promoting
translation of p65 transcript

We have previously demonstrated that high IMP3
GBM tumors are highly migratory/ invasive as seen by the
presence of IMP3 positive tumors cells in tumor infiltrating
front, perivascular and subpial regions [17]. In this work,
we set out to identify IMP3 targets that promote glioma
cell migration. An integrated bioinformatics approach was
used to identify IMP3 targets that encode transcription
factors since they are global regulators (Figure 1A).
Many RNA binding proteins regulate their targets at
mRNA translation level, and few of the identified IMP3
targets were also regulated at this level [17, 18]. We were
particularly keen to identify transcription factors whose
expression is regulated by IMP3 at the translation step. To
begin with, we utilized the PAR-CLIP data containing a
list of mRNAs with IMP3 binding sites and transcriptome
data of IMP3 silenced condition in HEK293 cells from
Hafner et al. [19]. Firstly, we selected transcripts that
contained IMP3 binding sites and whose transcript levels
are unaltered under IMP3 silenced conditions (n = 4132).
Next, this list was compared with transcription factor (TF)
data base [20] which identified a list of 404 TFs. We then
superimposed the TCGA GBM transcriptome data and
short listed 162 TFs with their transcript levels unaltered
between high- and low-IMP3 GBM tumors. These TFs
were arranged according to the number of IMP3 binding
sites present in their mRNA (Supplementary Table 1).
Among top 5 genes with 10 or more IMP3 binding sites,
we chose p65 (RELA) for further studies since p65 is a
www.impactjournals.com/oncotarget

To dissect the mechanism behind the regulation of
p65 and thereby NF-κB activity by IMP3, we checked the
p65 transcript and protein levels in IMP3 overexpressed
and knockdown conditions. p65 transcript levels in IMP3
overexpressing LN229 cells or IMP3 silenced U87,
A172, U138 and U343 cells was found to be unaltered
(Figure 2A and 2B). Additionally, there was no significant
difference in p65 transcript levels between low IMP3 and
high IMP3 GBM samples from TCGA and GSE22866
data sets (Supplementary Figure 1A and 1B). Moreover,
we observed no significant correlation between p65
protein and p65 transcript in our patient (GBM) cohort
as assessed by immunohistochemical analysis (IHC) and
qRT-PCR respectively (r = 0.2521, p = ns, Supplementary
Figure 1C). We next analysed the effect of IMP3 on p65
protein levels. While IMP3 overexpression resulted in
many fold increase in p65 protein in LN229, U373 and
U251 cells (Figure 2C), IMP3 silencing decreased the
p65 protein levels in U87, A172, U138 and U343 cells
(Figure 2D). Moreover, we found the protein levels
of p65 and IMP3 were significantly correlating in our
patient (GBM) cohort as assessed by IHC (r = 0.3648,
p = 0.0175, Supplementary Figure 1D). Furthermore,
this increased p65 protein is also functionally active, as
evident by nuclear translocation of p65 protein in LN229
and U251 cells with IMP3 overexpression (Supplementary
40470
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Figure 1E). Conversely, IMP3 knockdown led to
reduced nuclear p65 staining in A172 and U343 cells
(Supplementary Figure 1F). Thus, IMP3 increases the
NF-κB activity by increasing the p65 protein levels,
without any change in its transcript level. Further to
determine the mechanism behind increased p65 protein
levels in the presence of IMP3, we looked at the
translation and protein stability of p65. In knockdown
conditions of IMP3 in U138 cells, polysome analysis
revealed a significant decrease in the p65 transcript level
in polysome fraction and a concomitant increase of the
transcript in the non-polysome fraction (Figure 2E). To
check the effect of IMP3 levels on p65 protein stability,

cycloheximide chase experiment was performed. The rate
of degradation of p65 protein was seen to be similar in
IMP3 overexpression conditions (AdIMP3) and control
(AdGFP) LN229 cells, implying that IMP3 may not be
playing a role in regulating the protein stability of p65
(Figure 2F). Taken together, IMP3 increases the levels of
p65 protein by increasing its mRNA translation.

IMP3 binds to 3′UTR of p65 RNA
We next sought to investigate whether the increase
in p65 translation is mediated via direct binding of IMP3 to
the p65 transcript. The binding of IMP3 to p65 transcript

Figure 1: IMP3 expression increases NF-κB activity. (A) Schematic representation of the strategy employed to find the transcription

factor having putative IMP3 binding sites and unregulated at the level of RNA on IMP3 silencing (data provided in GSM545209 and
http://www.mirz.unibas.ch/restricted/clipdata/RESULTS/CLIP_microArray/index.html) [19]. (B) NF-κB luciferase reporter activity in
IMP3 overexpressing LN229 cells and in IMP3 silenced U87, T98G and U138 cells. For overexpression condition, NF-κB dependent
reporter luciferase activity was co-transfected with IMP3 overexpression construct. Increasing concentrations of IMP3 expressing vector
(1 μg and 2 μg) was used in the assay while keeping the reporter construct constant. Luciferase activity was measured after 48 h of
transfection. For IMP3 silenced condition, the readings were taken after 48 h of reporter transfection, while 96 h after siRNA transfection.
The activity obtained in vector control conditions was considered to be 1 and relative activities in increasing IMP3 conditions were plotted.
(C) Western blots showing IMP3 levels upon exogenous IMP3 overexpression (LN229 cells) or silenced conditions (U87, T98G and U138
cells). (D) Representative micrographs of migrated U138 cells in the mentioned conditions: siControl with control vector transfection,
siControl with p65 overexpression vector transfection, siIMP3 with control vector transfection and siIMP3 with p65 overexpression vector
transfection. (E) Quantitation of the number of migrated cells is represented as a bar graph. (F) Western blots confirming IMP3 silencing
and p65 overexpression in U138 cells. For all experiments, a student t-test was carried to assign statistical difference in observations made
in the conditions indicated. A p < 0.05 is represented with *p < 0.01 is represented as ** and p < 0.001 is represented as ***.
www.impactjournals.com/oncotarget
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was confirmed in the RNA immunoprecipitation assays,
where the p65 transcripts were found to be enriched in
IMP3 overexpressed fraction as compared to control
fractions in LN229 cells (Figure 3A). Further analysis of
p65 transcript sequence for the presence of IMP3 binding
sites revealed that there are 10 potential binding sites, with
four of them in 3′ UTR of the transcript (Supplementary
Figure 2A). Since IMP3 binding sites are generally
enriched in the 3′UTR of transcripts [19], and 3′UTR
sites have been implicated in translational regulation, we
investigated the importance of four sites present in the p65
3′UTR. Based on the conservation of the sites across the
species (Supplementary Figure 2B), the first three sites
were taken up for studies.
The activity from a reporter construct with p65
3′UTR having these three sites downstream to Renilla
luciferase gene (Figure 3B) is induced in LN229 cells

overexpressing IMP3 and is reduced in IMP3 silenced
T98G cells (Figure 3C). UV crosslinking experiments
using purified IMP3 protein, and radioactively labelled
in vitro transcribed RNA corresponding to these three sites
revealed that all the three sites are capable of binding to
IMP3 (Figure 3D, left panel). This binding is specific as the
cold RNA of the same site competed efficiently the binding
by IMP3 (Figure 3E, right panel). Further, IMP3 failed to
bind to a non-specific RNA (Supplementary Figure 2C).
The importance of the predicted consensus sequence [19]
in these sites for the specific binding by IMP3 was further
confirmed by altering the important residues. Conversion
of the first two residues CA to AC (Figure 3E) of the
four nucleotide consensus 5′-CAUH-3′ [19] significantly
abolished the binding by IMP3 (Figure 3F). To test the
biological significance of IMP3 binding to p65 3′UTR,
we tested the ability of IMP3 to activate a luciferase

Figure 2: Mechanism of p65 expression regulation by IMP3. (A) Transcript levels of p65 and IMP3 in IMP3 overexpressing
LN229 cells as assessed by qRT-PCR. Log2 ratio of transcript levels in AdIMP3 infected cells relative to AdGFP infected cells was plotted.
(B) Transcript levels of p65 and IMP3 in IMP3 silenced conditions in glioma cell lines like U87, A172, U138 and U343. Measurement was
done using qRT-PCR and the log2 ratio of transcript levels in siIMP3 transfected cells relative to siControl transfected cells was plotted.
(C) Western blotting analysis of lysates from cell lines ectopically overexpressing IMP3 for the levels of IMP3, p65 and loading controls
(Actin or PCNA). (D) Western blots showing levels of p65 and actin after IMP3 silencing. (E) Polysome analysis to measure the changes
in p65 transcript translation in IMP3 knockdown condition was performed. p65 transcript levels were measured in non-polysome and
polysome fraction in IMP3 and control knockdown condition by qRT-PCR. Log2 ratio of transcript levels in siIMP3 transfected cells
relative to siControl transfected cells was plotted. (F) Western blot analysis followed by cycloheximide chase experiment. p65 levels
were measured in these lysates. Quantitation of the remaining p65 expression (at 2, 4 and 6 hours) when compared to 0 hours in the two
conditions is shown as the graph (right). For all experiments, a student t-test was carried to assign statistical difference in observations made
in the conditions indicated. A p < 0.05 is represented with *p < 0.01 is represented as ** and p < 0.001 is represented as ***.
www.impactjournals.com/oncotarget
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reporter construct carrying p65 3′UTR with the mutation
in the IMP3 binding consensus as described earlier. To
our surprise, site 1 mutation did not significantly affect
the ability of IMP3 to activate the reporter activity,
while both site 2 or 3 mutations abolished the ability of
IMP3 to activate the reporter activity (Figure 3G). These
observations underscore the importance of IMP3 binding
to site 2 and site 3 over site 1 in physiological conditions.
Thus, we conclude from these experiments that IMP3

binds to the p65 3′UTR directly, and this binding may be
important for its regulation on p65 expression.

A positive feedback loop between IMP3 and
NF-κB pathway
We then investigated the possibility of IMP3 being
transcriptionally activated by NF-κB pathway involving
a positive feedback loop. To assess this possibility, we

Figure 3: IMP3 binds to p65 transcript. (A) RNA immuno-precipitation (RIP) followed by qRT-PCR in LN229 cells transduced with

AdGFP or AdIMP3 virus. RIP was performed 48 h post infection. p65 transcript levels were measured (qRT-PCR) in control antibody (IgG)
or IMP3 antibody immunoprecipitated fractions from GFP virus and IMP3 virus infected cells and depicted. (B) Schematic representation of
the luciferase construct used, where partial p65 3′UTR containing 3 putative IMP3 binding sites was cloned downstream to Renilla luciferase
gene. (C) Construct carrying first three putative IMP3 binding sites in p65 3′UTR was transfected in ectopically IMP3 overexpressing
cells (LN229) and IMP3 silenced cells (T98G). Luciferase readings were taken 48 h after reporter transfection and relative readings were
plotted. (D) Phosphorimages after RNA-protein UV crosslinking experiments were performed. α 32P-labelled RNAs (~150 bases each)
of corresponding sites were incubated in the absence or increasing concentrations of purified IMP3 protein. The radiolabel RNA-protein
complexes were resolved on SDS-10% PAGE gels and phosphorimaging was performed (three left panels). α 32P-labelled RNA was also
UV cross-linked to recombinant purified IMP3 protein, with 100, 200 and 400 fold molar excess of unlabelled same site RNA (cold RNA).
Images after phosphorimaging for these experiments are also shown (three right panels). (E) Partial representation of the sites with four
nucleotide consensus for IMP3 binding shown in bold letters. The first two mutated bases in the consensus are underlined in the mutated
sequence. (F) Phosphorimages after RNA UV crosslinking experiments with wild type or the mutant RNA probes for the three sites. (G)
Luciferase assay performed in IMP3 overexpressing LN229 cells transfected with wild-type or mutated 3′UTR plasmids. Each plasmid only
had one site mutated as indicated, with the other two sites having wild type sequence. Luciferase readings were taken after 48 h of reporter
plasmid transfection. Relative luciferase readings were calculated and depicted as bar graphs. For all experiments, a student t-test was carried
to assign statistical difference in observations made in the conditions indicated. A p < 0.05 is represented with *p < 0.01 is represented as
** and p < 0.001 is represented as ***.
www.impactjournals.com/oncotarget
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sub-cloned partial region of IMP3 promoter (−987 to
+66) having four p65 binding sites upstream to Fire-fly
Luciferase gene of pGL3-Basic vector to construct an
IMP3 promoter-reporter construct (Figure 4A). Treatment
of U87 and HCT116 cells with a pharmacological
inhibitor to NF-κB pathway, BAY 11-7082 (an inhibitor
of IKK complex activity) resulted in a dose dependent
inhibition of luciferase activity from IMP3 promoterreporter construct (Figure 4B). BAY 11-7082 treatment
also resulted in reduced IMP3 transcript (U343 and H1299
cells) and protein levels (U87, U343 and H1299 cells)
(Figure 4C and 4D). As expected, under these conditions,
BAY 11-7082 treatment inhibited reporter activity from
NFκB-dependent reporter (Supplementary Figure 3A).
Further, activation of NF-κB pathway by TNF-α led to
increase in IMP3 RNA and protein levels in LN229 and
U251 cells (Figure 4E and 4F). TNF-α treatment resulted
in the activation of reporter activity from NFκB-dependent
reporter as anticipated (Supplementary Figure 3B).
Additionally, a dominant negative form of IκB (IκBSR),
an inhibitor of NF-κB pathway, decreased IMP3 transcript
levels in U251 and U87 glioma cells (Figure 4G). We
also found a significant positive correlation between p65
protein (as determined by immunohistochemistry) and
IMP3 transcript levels (as determined by qRT-PCR) in our
cohort of GBM patient samples (r = 0.2976, p = 0.0304,
Supplementary Figure 3C). We went ahead to check
if p65 binds directly to IMP3 promoter by performing
ChIP-qPCR. We found enhanced p65 occupancy on the
IMP3 promoter region both in endogenous and TNF-α
activated condition in U87 cells (Figure 4H). Analysis
of IMP3 promoter region that was amplified for ChIPqPCR in UCSC genome browser [25] also showed an
enrichment of activated histone marks (H3K27Ac marks)
(Supplementary Figure 3D). To investigate whether
IMP3 is itself able to increase its own transcription via
p65, we checked for the IMP3 reporter activity in IMP3
overexpression conditions. We see an increased IMP3
promoter dependent luciferase reporter activity in IMP3
overexpression condition in LN229 cells (Figure 4I) and
this increase was abrogated by BAY 11-7082 treatment
(Figure 4J). These results demonstrate the existence of a
probable positive feedback loop between IMP3 and NFκB pathway in GBM.

were 73 RBPs upregulated and 73 RBPs downregulated
in GSC in comparison to ahNSC (Figure 5A). Among the
GSC specific upregulated RBPs, we found IMP3 to be
the most upregulated (Fold change in GSC over ahNSC =
92.94), suggesting that IMP3 may play an important role
in GSC maintenance (Figure 5A; Supplementary Table 2).
To confirm the association between IMP3 and GSCs, we
carried out Gene Set Enrichment Analysis (GSEA) for the
possible enrichment of gene expression profile of CD133+
(a marker for glioma stem-like cells) glioma cells [32],
in IMP3 expressing glioma tumors. We found a positive
enrichment of upregulated genes in CD133+ glioma cells
(CD133+_up) in GBMs with high levels of IMP3 transcripts
(IMP3 high) (Supplementary Figure 4A). In contrast,
GBM tumors with low levels of IMP3 transcripts (IMP3
low) had a positive enrichment of downregulated genes in
CD133+ glioma cells (CD133+_down) (Supplementary
Figure 4B). To experimentally validate the importance of
IMP3 in GSC maintenance, we tested the effect of IMP3
silencing on the ability of GSCs (SK1035 and MGG4)
to grow as neurospheres. IMP3 silencing inhibited GSC
neurosphere growth significantly both in terms of number
and size (Figure 5B–5D). SK1035 and MGG4 GSCs have
been described previously [33, 34] and were grown as
neurospheres, which are known to enrich cells with stemlike characteristics. IMP3 silencing also resulted in the
downregulation of four glioma reprogramming transcription
factors- OLIG2, POU3F2, SOX2 and SALL2 in GSCs
(Figure 5E). These results were also reproduced in glioma
cell lines, where a diminished neurosphere forming capacity
was observed in A172, U87 and U251 cells transfected with
siIMP3 (Supplementary Figure 4C and 4D). Next, we tested
whether p65 is also a critical downstream mediator of IMP3
in GSC maintenance using SK1035. The inhibitory effect
of IMP3 depletion on neurosphere formation was tested
in the presence of exogenously expressed p65 transcribed
from a 3′UTR-less construct. IMP3 downregulation led to
significant decrease in number of neurospheres as observed
before (Figure 6A and 6B; compare bar 2 with 1). However,
simultaneous exogenous overexpression of p65 rescued the
neurosphere formation significantly (Figure 6A and 6B;
compare bar 4 with 2). qRT-PCR confirmed the efficient
silencing of IMP3 and p65 overexpression (Figure 6C).
We also observed an increase in IMP3 transcript in p65
overexpression condition establishing the regulation of
IMP3 transcription by p65 in GSCs also (Figure 6C).The
spheres formed upon p65 overexpression in IMP3 silenced
condition indeed showed increased levels of SOX2,
SALL2 and POU3F2 (Figure 6D). Next, we also checked
if migration capacity of GSCs is regulated by IMP3.
IMP3 knockdown led to decreased migration of SK1035
GSCs (Figure 6E and 6F; compare bar 1 with 2). Further,
we also observed an alleviation of reduction in migratory
potential with p65 overexpression in IMP3 depleted cells
(Figure 6E and 6F; compare bar 2 with 4). Taken together,
these results underscore the importance of IMP3-p65

IMP3-p65 cascade also regulates glioma stemlike cells (GSC) maintenance and migration
Since GSCs show enhanced migratory property and
IMP3 promotes migration of glioma cells, we were intrigued
if there is any association between IMP3-p65 cascade and
GSCs [17, 26–28]. We examined the transcript levels of
1756 RNA binding proteins (RBPs) [29, 30] derived from
GSE31262 microarray database, which provides transcript
profile of five adult human neural stem cell lines (ahNSC)
and nine glioblastoma stem cells lines (GSC) [31]. There
www.impactjournals.com/oncotarget
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cascade in maintenance of glioma stem-like cells and their
migratory capacity.

and is also associated with malignant and recurrent tumors
[17, 35–41]. IMP3, being an RNA binding protein, has
promiscuous binding and a plethora of target transcripts
[18, 19]. From the multiple targets, we were interested
to identify a global regulator, regulated by IMP3 at the
level of translation, which may be playing a crucial role in
migration of glioma cells. We focussed our efforts to IMP3

DISCUSSION
IMP3 is an oncofetal RBP, implicated in migration,
invasion, angiogenesis, cancer stem-like cell maintenance

Figure 4: IMP3 gene expression is regulated by NF-κB activity and both participate in a positive feedback loop.

(A) Schematic representation of IMP3 promoter showing putative p65 binding sites revealed by bioinformatics analysis. The positions
relative to Transcription Start Site (TSS) are indicated in the boxes. The putative consensus sequence of NF-κB binding in each of the sites
is shown in red. (B) IMP3 promoter dependent luciferase activity of the cells transfected with IMP3 promoter reporter was measured after
treatment with BAY 11-7082 at the indicated concentrations. Luciferase assays were performed 48 h after transfection and 12 h of inhibitor
treatment. Luciferase readings were normalized to β-galactosidase readings present in the lysate. (C) Measurement of IMP3 transcript
levels after treatment of U343 cells (left panel) and H1299 cells (right panel) with BAY 11-7082 (10 µM) at the indicated time points using
qRT-PCR was performed. (D) Western blot analysis was performed to measure IMP3 protein levels in lysates of cells treated with BAY 117082 (10 µM) for indicated time points. (E) Transcript levels of IMP3 in cells treated with TNF-α (10 ng/ml) for 4 h in LN229 and U251
cells, as measured using qRT-PCR. (F) IMP3 protein levels in lysates made from cells treated with TNF-α (10 ng/ml) for the indicated
time points. (G) Transcript levels of IMP3 in U251 and U87 cells after 48 h of IκB super repressor (IκBSR) transfection. Measurements of
transcript levels were made using qRT-PCR. (H) ChIP was performed in untreated and TNF-α (10 ng/ml) treated U87 cells. qRT-PCR was
performed to check the levels of region of IMP3 promoter amplified in p65 and control (IgG) immuno-precipitated chromatin. Relative
enrichment of IMP3 promoter region in p65 pull-down over IgG pull-down conditions is shown in TNF-α treated and untreated cells.
(I) Relative luciferase activity measurements of IMP3 promoter reporter in LN229 cells with ectopic overexpression of IMP3. All readings
were recorded after 48 h of reporter transfection. (J) Relative luciferase activity measurements of IMP3 promoter reporter in LN229 cells
ectopically expressing IMP3 treated or untreated with BAY 11-7082 (10 µM). All readings were recorded after 48 h of reporter transfection
and 12 h of inhibitor treatment. For all experiments, a student t-test was carried to assign statistical difference in observations made in the
conditions indicated. A p < 0.05 is represented with *p < 0.01 is represented as ** and p < 0.001 is represented as ***.
www.impactjournals.com/oncotarget
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mediated migration as our previously published results in
GBM clearly reflect the importance of this molecule in
this hallmark of cancer [17]. Our integrated bioinformatics
approach identified p65, a transcription factor in NF-κB
pathway to be a putative target of IMP3. NF-κB pathway
activates a cascade of genes important during development
and is also associated with aggressive and resistant tumors
[42–44]. In addition, the level of NF-κB activation is
directly proportional to tumor aggressiveness [45], and
also implicated in cancer stem-like cell maintenance
[24, 46–48]. In GBM, NF-κB pathway is constitutively
active in a subset of tumors and represents a survival
signal sustaining tumor growth [23]. It is also reported
to play an important role in migration, invasion, GSC
survival and chemoradiotherapy by its ability to activate

various important oncogenes, including IL-6, IGFBP-2
and c-myc, all of which are known regulators of migration
capacity, glioma stem-like cells and are associated with
tumor aggressiveness [49–51]. These reports motivated us
to validate p65 as a target for IMP3 and as its downstream
mediator in rendering migratory potential to the cells.
Our findings in glioma cells with IMP3 overexpression
and silencing unequivocally establish IMP3 as a positive
modulator of NF-κB signalling by increasing the
translation of p65 transcript. These results are in coherence
with the observations made by Pei et al., where they have
shown that IMP3 activates NF-κB pathway and contributes
to migration of renal cell carcinoma cells [52]. Our p65
rescue experiment in IMP3 depleted U138 glioma cells
clearly reflects the importance of the molecule downstream

Figure 5: IMP3 expression is associated with GSC maintenance. (A) Heat map showing significantly differentially expressed

RNA binding proteins (73 up-regulated and 73 downregulated) between normal neural stem cells (n = 5) and glioma stem like cells
(n = 8) from GSE31262. Log2 ratio values of expression are plotted ranging from −2 (green: downregulated) to +2 (red: upregulated).
(b) Representative images showing decrease in sphere number and diameter after IMP3 silencing mediated by siRNA for SK1035 and
MGG4 GSCs. (C) Quantitative representation of the relative decrease in sphere number after IMP3 depletion in GSCs using bar graph.
The number of spheres in untreated condition was considered to be 1 and number of spheres in knockdown condition is plotted relative to
it. (D) Number of spheres falling in different size categories (as per diameter in µm) plotted as bar graphs. Note that in IMP3 knockdown
condition there is a general decrease in sphere diameter, but the number of spheres with bigger diameter is affected more severely in both
SK1035 and MGG4 GSCs. (E) qRT-PCR analysis of transcript levels of known glioma stem-like cell markers upon IMP3 knockdown in
SK1035 and MGG4 GSCs. Log2 ratio values of the transcript levels are plotted. For all experiments, a student t-test was carried to assign
statistical difference in observations made in the conditions indicated. A p < 0.05 is represented with *p < 0.01 is represented as ** and
p < 0.001 is represented as ***.
www.impactjournals.com/oncotarget
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to IMP3 in imparting migratory potential to these cells.
We also show that IMP3 has a role to play in GSC
maintenance and migration. GSCs are known for high
migratory potential and therapy resistance [4, 27, 53] thus
the association of IMP3 with GSCs makes it a lucrative
target for therapy.
Another aspect investigated is the binding of IMP3
to p65 3′UTR. Our results establish a specific binding
of IMP3 to three sites on the p65 3′UTR. In luciferase
assays with p65 3′UTR, we observed that mutation in
site 1 did not significantly alter the enhanced activity in
IMP3 overexpression conditions (as observed in wild type
3′UTR construct). Conversely, mutation in either site 2 or
site 3 significantly impaired the IMP3 mediated increase in
luciferase activity. This signifies the importance of IMP3
binding to these two sites (site 2 and site 3) in mediating

its regulation in the cells. Though there may be various
reasons behind this observation, one of the scenarios that
we hypothesize is that IMP3 may be binding to site 2 and
site 3 in a pseudodimeric configuration as proposed for
IMP1 (a paralogue of IMP3) to its target [54]. Though the
exact mechanism by which IMP3 promotes translation of
target transcripts is not known, we hypothesize that it may
involve recruitment of auxiliary proteins that may act as
translation activators.
GBM tumors have high expression of p65 and IMP3
proteins [17, 45]. Our results explicitly establish p65 as a
target of IMP3 at the level of translation and also IMP3
as a transcriptional target of p65. In light of the evidence
provided, we conclude the existence of a positive feedback
loop between IMP3 and p65. The presence of such a
positive feedback loop in GBM tumors will further fuel

Figure 6: IMP3 regulates GSC maintenance and migration via p65. (A) Representative images of SK1035 neurospheres formed

in the four mentioned conditions: siControl with control vector transfection, siControl with p65 overexpression vector transfection, siIMP3
with control vector transfection and siIMP3 with p65 overexpression vector transfection. (B) Quantification of neurospheres formed in the
indicated conditions. (C, D) Transcript levels of IMP3, p65, SOX2, SALL2 and POU3F2 genes in SK1035 under the mentioned conditions:
siControl with control vector transfection, siControl with p65 overexpression vector transfection, siIMP3 with control vector transfection
and siIMP3 with p65 overexpression vector transfection. (E) Representative micrographs of migrated SK1035 GSCs in the mentioned
conditions: siControl with control vector transfection, siControl with p65 overexpression vector transfection, siIMP3 with control vector
transfection and siIMP3 with p65 overexpression vector transfection. (F) Quantitation of the number of migrated cells is represented as a
bar graph. For all experiments, a student t-test was carried to assign statistical difference in observations made in the conditions indicated.
A p < 0.05 is represented with *p < 0.01 is represented as ** and p < 0.001 is represented as ***.
www.impactjournals.com/oncotarget
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the belligerent state of the tumor. Thus, the disruption
of this axis should bring down the aggressiveness of
the tumor and its relapse. Taken together, we propose a
model wherein IMP3 may enhance the translation of
p65 thus contributing to activation of NF-kB pathway in
GBM tumors. This may result in transcription of various
oncogenes including cytokines and IMP3 itself. Thus our
study establishes that the intricate regulation between
IMP3 and NF-κB pathway is essential for migration of
glioma cells (Figure 7).
The importance of this study relies on the fact
that there are limitations in the utilization of NF-κB
inhibitors for the management of various cancers. Preclinical trials of NF-κB inhibitors have shown promising
reduction in tumor burden, but serious concerns about
side effects are still raised [55]. These observations
thrust upon the importance of alternate strategies for
NF-κB pathway inhibition. Molecules targeting IMP3
could be considered for attenuating and disrupting
NF-κB thus ensuring pronounced tumor specific inhibition
with minimum side effects. Previously published report
from our group demonstrated that IMP3 depletion results

in enhanced sensitivity to chemotherapy in glioma cell
lines [17]. Current study establishes that IMP3 is critical
for migration of both differentiated and glioma stemlike cells. Thus, IMP3 depletion may render even the
GSCs, which have higher migratory potential and are
refractory to the existing therapeutic modalities sensitive
to chemotherapy. Further, it has been shown that peptides
derived from IMP3 induce immune response of helper
T cells and cytotoxic T lymphocytes resulting in better
clinical response in esophageal cancer [56, 57]. Hence,
IMP3 targeting may prove to be useful as an adjuvant
therapy leading to targeting highly infiltrative cells thus
improving the median survival, quality of life of patients
and reducing the probability of recurrence in a patient.

MATERIALS AND METHODS
Culture of adherent cells and glioma stem-like cells
293T, U87 and HCT116 (Sigma); LN229, U138,
U343, U251 (from Dr. Abhijit Guha’s laboratory), were
grown in Dulbecco’s modified Eagle Medium (DMEM)

Figure 7: Proposed model of regulation of p65 and IMP3 in GBM tumors. Low IMP3 expressing GBM tumors are relatively

less invasive in nature. High IMP3 expressing GBM tumors will have high IMP3 protein resulting in enhanced translation of p65 transcript,
and thus an increased expression of p65 protein is observed. The activated p65 translocates to the nucleus and induces the expression of
NF-κB target genes including several cytokines and oncogenes. IMP3 also acts as another transcriptional target of p65 and the levels of
both molecules are regulated in a positive feedback loop (depicted by long red arrow). This contributes in enhanced glioma cell migration
and GSC maintenance in high IMP3 expressing GBM tumors.
www.impactjournals.com/oncotarget
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supplemented with 10% Foetal Bovine Serum (10% FBS),
penicillin (Sigma, U.S.A.), gentamicin (Sigma, U.S.A.)
and streptomycin (Sigma, U.S.A.) at 37°C in a humidified
atmosphere with 5% CO2. Primary tumor GSCs were kindly
given by Dr. Santosh Kesari (University of California,
San Diego) and Dr. Wakimoto H. (Massachusetts General
Hospital, Boston). They were cultured in Neurobasal
medium (Invitrogen, U.S.A.) supplemented with 3 mmol/L
L-Glutamine (Invitrogen, U.S.A.), basic fibroblast growth
factor (bFGF; 20 ng/ml, Promega), epidermal growth factor
(EGF; 20 ng/ml; Promega), 1X B27 supplement (Invitrogen,
U.S.A.), 0.5 × N-2 (Invitrogen, U.S.A.), 2 μg/mL Heparin
(Sigma, U.S.A.), penicillin, gentamicin and streptomycin
in ultra-low attachment plates (Corning, U.S.A.). SK1035
neurospheres were passaged by mechanical dissociation after
days 8–10, while chemical dissociation kit (Catalog# 05707,
STEMCELL technologies, U.S.A.) was used for dissociation
of MGG4. Fresh medium was supplemented every 2–3 days.

earlier in previously published literature [17]. BAY
11-7082 (Calbiochem, U.S.A.) and TNF-α (Cell Signaling
Technology, U.S.A.) were also used in this study.

RNA isolation and real-time quantitative RT-PCR
analysis
Total RNA was isolated using TRI reagent (Sigma,
U.S.A.) and 2 µg of RNA was reverse transcribed using
the High capacity cDNA reverse transcription kit (Life
technologies, USA) according to the manufacturer’s
protocol. qRT-PCR was performed using the ABI PRISM
7900 HT Sequence Detection System (Life technologies,
USA). Expression of the genes of interest was analyzed
and normalized to 18S rRNA, ATP5G1, AGPAT or
RPL35a as internal control genes following the ΔΔCt
method [58]. The primer sequences used for p65 and IMP3
are p65 (forward): GAAGAAGAGTCCTTTCAGCG,
p65 (reverse): GGGAGGACGTAAAGGGATAG, IMP3
(forward): CACCTCTGCGGCTTGTAAGTC, IMP3
(reverse): CAGCGTCAATTCCTGCAATGG, POU3F2
(forward): TGACGATCTCCACGCAGTAG, POU3F2
(reverse):
GGCAGAAAGCTGTCCAAGT,
SOX2
(forward): AACCCCAAGATGCACAACTC, SOX2
(reverse): GCTTAGCCTCGTCGATGAAC, SALL2
(forward): TAATCTCGGACTGCGAAGG, SALL2
(reverse): TAGAACATGCGTTCTGGTGG, OLIG2
(forward): CCAGAGCCCGATGACCTTTT, OLIG2
(reverse): AGGACGACTTGAAGCCACTG

Human tumor samples
Source of tumor samples are GBM patients operated
at National Institute of Mental Health and Neurosciences
(NIMHANS) and Sri Sathya Sai Institute of Higher
Medical Sciences (SSSIHMS), Bangalore, India. Tissues
were bisected and one portion was used for placed in
RNA later (Ambion Inc., USA), stored at −70°C and used
for RNA isolation, while the other half was fixed in 10%
buffered neutral formalin, processed for paraffin sections
and was used for immunohistochemistry (IHC). The study
was approved by the ethics committee of NIMHANS
and SSSIHMS (the two clinical centres) and the consent
of the patients was obtained as per the Institute Ethical
Committee guidelines and approval. For assessing the
transcript levels of various genes (IMP3 and RELA) in
tumor samples we had used forty six GBM samples.

Western blotting
Equal amount of lysates (quantified using Bradford
reagent) were resolved on SDS-PAGE gels, transferred
on PVDF membrane and probed with antibodies against
IMP3 (Catalog # HPA002037, Sigma, U.S.A.), actin
(Catalog # A3854, Sigma, U.S.A.), PCNA (Catalog #
NA-03, Calbiochem, U.S.A.) and p65 (Catalog # 3034S,
Cell Signaling Technology, U.S.A.). For cycloheximide
chase experiment, cylcoheximide (50 µg/ml) (Sigma,
U.S.A.) was added to the cells and the cells were harvested
at the indicated time points. The lysates were made and the
western blotting was performed. The blots were probed for
p65 and the loading control.

Plasmids and other reagents
IMP3 overexpression construct used has been
described earlier [17]. IMP3 promoter reporter was
procured from Switch Gear genomics (S717055) and subcloned into pGL3 Basic vector (Promega, U.S.A.). NF-κB
dependent luciferase reporter vector was a kind gift from
Dr. Balaji, IISc, India. IκB super-repressor (IκBSR) was
kindly provided by Dr. Inder Verma. pAG23 RELA 3ʹUTR
was a gift from David Bartel (Addgene plasmid # 14505).
Control siRNA pool (Catalog # D-001810-10-50)
and siRNA pool used against IMP3 (GenbankTM accession
number NM_006547; Catalog # L-003976-00-0050) were
purchased from GE HealthCare Dharmacon Inc (OnTARGET plus Human siRNA SMART pool). These siRNA
against IMP3 contains a pool of 4 siRNAs. The details of
these are given in previously published literature [17]. GFP
Adenovirus and IMP3 adenovirus used were described

www.impactjournals.com/oncotarget

Immunofluorescence staining
Cells were fixed with 4% paraformaldehyde,
washed with Tris-buffered saline, and incubated with
anti-p65 (Catalog # 8242, Cell Signaling Technology,
U.S.A.). Primary antibodies were incubated for 16 h at
4°C followed by detection with Alexa 488 anti-rabbit
(Invitrogen). Nuclei were stained with DAPI (Sigma) and
slides were mounted using anti-fade (Invitrogen). Images
were taken with a confocal microscope (Leica, U.S.A.).

40479

Oncotarget

Luciferase reporter assay

chilled methanol (30 min) and stained with 0.1% crystal
violet (30 min). Representative images were taken under
light microscope and migrated cells were counted. The
assay was performed in duplicates.

IMP3 promoter region was purchased from Switch
gear genomics and the promoter region was sub-cloned in
pGL3-Basic vector. NF-κB reporter luciferase construct
was a kind gift from Dr. K.N. Balaji (IISc., Bangalore
India). Luciferase assays were performed using reporter
lysis buffer RLB (catalog # E3971, Promega, U.S.A.)
and Luciferase Assay reagent (LAR, catalog # E1500,
Promega, U.S.A.) as per manufacturer’s instructions.
Briefly, plasmids were transfected in the cells plated in
12 well plates using Lipofectamine 2000 (a total of
2–4 μg in each well). Cells were harvested after 48 h of
transfection and lysates were made. Luciferase readings
were recorded using luminometer. β-galactosidase assays
or Renilla luciferase readings were performed to normalize
the transfection differences. These assays were carried in
duplicates.
For 3′UTR luciferase assays, the plasmid was
obtained for Addgene. The wild type or mutated 3′UTR
plasmids (containing Renilla luciferase) were cotransfected with pCMV-luc (having firefly luciferase
gene) and the luciferase assays were performed using dual
luciferase assay kit (Catalog # E1910, Promega, U.S.A.).

IMP3 protein purification
pET42a-IMP3 was obtained as a gift from Jan
Christiansen. Untagged protein was purified as mentioned
before without any modifications [59].

In vitro RNA transcription and site directed
mutagenesis
DNA fragments were obtained by amplifying
the site 1, site 2 and site 3 from the pAG23 RELA 3′
UTR plasmid. Amplification of region from each site
was done using forward primer having T7 promoter
which were then used as template in vitro transcription.
These transcripts were also labelled using α-32P
during the reaction. The transcription reactions were
carried out using T7 RNA polymerase (Promega,
U.S.A.) according to the manufacturer’s instructions.
Primers used for amplification for templates for
in vitro transcription are site 1 (forward): TAATACG
ACTCACTATAGGGAGATTTTATTGTCAGTATCTG,
site 1 (reverse): GTTCCCTACAGAGAAGGGAGCT
GACC, site 2 (forward): TAATACGACTCACTATA
GGGAGAGGAGGTAAGGCCTTTGAGCC, site 2
(reverse): CGCTGGTGTTAGGCACAGGGACAATGCC,
site 3 (forward): TAATACGACTCACTATAGGGAGAG
TGCCTAACACCAGCG, site 3 (reverse): GGAACTGAC
CAGACCAAACCCCTTCTGG.
Mutation of IMP3 binding consensus in three
sites of p65 3′UTR was performed by site directed
mutagenesis using the QuickChange® XL Site-directed
Mutagenesis Kit (Catalog # 200516) from Stratagene
(Agilent Technologies, U.S.A.) following manufacturer’s
instructions. The primers used for mutagenesis are - site
1: GGAGGTGCTTAAGCAGAAGACTTAACTTCTCT
GGAAAGGG, site 2: GTCTTCCATCATGGATTACTTA
CAGCTTAATCAAAATAACGCC and site 3: TCT
TTCCTTGCTCAACACTGGCTGAAGGAAACCAG.
The template used was pAG23 RELA 3′UTR plasmid.

Transfection of GSCs, neurosphere assay and
sphere diameter measurement
GSCs transfections were carried out in single cell
suspension state for both siRNA and plasmids. After
48 h of transfection, the aggregates formed were
dissociated into single cells, counted and equal numbers
of cells were plated at a density of 4 cells/µl in 24-well or
6-well plate. Number of spheres was counted after 7 days of
plating. Again, fresh medium was added to the wells every
2–3 days. Sphere diameter measurements were done with
ImageJ software. Number of spheres above the median
diameter were calculated and plotted for total number of
spheres. These assays were performed in duplicates.

Migration of glioma cells and GSCs
U138 glioma cells and SK1035 GSCs were
transfected with control siRNA or siRNA against IMP3.
After 36 h of transfection, cells were plated for p65
overexpression transfection (5 μg in a 35 mm). After 36
h of p65 transfection, cells were made into single cell
suspension and 25,000 cells were plated for migration in
a Corning® BioCoat™ Control Inserts with 8.0 µm PET
Membrane (Catalog # 354578, Corning, U.S.A.). Upper
chamber contained incomplete medium required for the
growth of respective cell lines, while the lower chamber
contained medium with 20% serum. Migration of cells
was observed after 8 h of incubation in 37°C incubator.
Cells from the upper side of the chamber were gently
removed, while those in the lower side were fixed using
www.impactjournals.com/oncotarget

UV crosslinking of RNA with IMP3 protein
For UV crosslinking, α-32P UTP-labelled radioactive
probes of the IMP3 binding sites in p65 3′UTR were
in vitro transcribed. The DNA substrates used were
LN229 cDNA, wild type or mutant RELA 3′UTR plasmid
(Addgene). The protocol for UV crosslinking was
followed as described earlier [60]. Briefly, α-32P UTPlabelled RNA probes were incubated with the purified
IMP3 protein (1 × = 2.35 pmol) in RNA binding buffer
at 30°C for RNA-protein complex formation. Protein was
40480
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quantified using Bradford reagent in spectrophotometer.
RNA and protein were subjected to UV crosslinking for
20 minutes. This was followed by RNase A treatment
(30 µg) at 37°C for 30 min to remove the unbound RNA.
Protein-RNA complexes were resolved on SDS-10%
PAGE. The gel was subjected to phosphorimaging and
analyzed.

and reverse, 5′- TAGGAGGAGGCGGGATTAGC -3′;
amplicon size-115 bp) were used and qRT-PCR was done
as described previously. Fold enrichment method was used
to calculate the p65 binding to IMP3 promoter in different
conditions.

RNA immunoprecipitation (RIP)

PAR-CLIP data (GSM545209) and knockdown data
for IMP3 [19] was downloaded from starBase v2.0 (http://
starbase.sysu.edu.cn/) [61] and http://www.mirz.unibas.
ch/restricted/clipdata/RESULTS/CLIP_microArray/
index.html respectively and analysed. In this analysis,
genes having non-significant p-value (p-value > 0.05)
for differential expression mock and IMP3 knockdown
conditions and the genes having difference in Log2
ratios in range of – 0.57 and 0.57 between these two
conditions were taken as unregulated. Stringent cut off
(T2C frequency > 0.5) for IMP3 binding to transcripts
was used to shortlist genes. Moreover, the list of animal
transcription factors was retrieved from AnimalTFDB
[20]. Transcription factor list was arranged using the
number of binding sites present in the transcript as
reflected by T2C positions.
Differential expression of RNA binding proteins
in NSC versus GSC was performed using GSE31262.
Publically available microarray datasets like TCGA
(https://tcga-data.nci.nih.gov) and GSE22866 [62] were
used for plotting RNA expression of p65 in IMP3 high
and low tumors. The datasets, were stratified into high and
low IMP3 expressing tumors with almost equal number of
GBM tumor samples: TCGA (high IMP3: n = 147; low
IMP3: n =176) and GSE22866 (high IMP3: n = 16; low
IMP3: n = 12).
MEGA 6 was used to represent the conservation of
consensus sequence in IMP3 binding sites at p65 3′UTR.
Prediction of p65 binding sites on IMP3 promoter was
performed using Physbinder (http://bioit.dmbr.ugent.be/
physbinder/index.php) [63].
A computational approach of GSEA [64] was
undertaken to evaluate the TCGA Agilent microarray
data for the enrichment of genes up regulated and down
regulated in GSCs in IMP3 high and low defined tumor
groups respectively. Defined gene sets (Yan_UP_IN_
CD133_GBM [65], Yan_DOWN_IN_CD133_GBM
[65], BEIER_GLIOMA_STEM_CELL_UP [66] and
BEIER_GLIOMA_STEM_CELL_DOWN [66]) from
the Molecular Signature Database version 3.0 (MSigDB)
were used to evaluate whether statistically significant
differences existed between the enrichment of gene sets
in the two groups of High and Low IMP3 tumors. We
acknowledge our use of the gene set enrichment analysis,
GSEA software, and Molecular Signature Database
(MSigDB) [64] (http://www.broad.mit.edu/gsea/).

Bioinformatics analysis

Protocol was followed as described earlier [17].
Briefly, LN229 cells were infected with AdGFP or
AdIMP3. After 48 h, cells were lysed in lysis buffer
containing 100 mM KCl, 5 mM MgCl2, 10 mM HEPES
pH = 7.0, 0.05% Nonidet P-40, 1 mM DTT, 100 U/mL
RNase inhibitor, and 1X protease inhibitor cocktail. The
lysates were spun at 13000 rpm for 30 minutes and protein
concentration of supernatants was quantified. Supernatants
from each condition (containing equal protein
concentration) were incubated with IgG control antibody
and anti-IMP3 antibody (AntiIMP3, N19, sc-47893, Santa
Cruz) at 4°C overnight. BSA blocked Protein-G sepharose
beads were added to immobilize the immunocomplexes
formed. Washes with lysis buffer containing 10%
NP-40 were given, which was followed by Proteinase K
and DNase treatment. Finally, RNA was extracted using
TRI reagent and precipitated using alcohol. cDNA was
made using this RNA as template and used for qRT-PCR
for the assessment of the p65 transcript (Primer sequences
forward: GAAGAAGAGTCCTTTCAGCG, reverse:
GGGAGGACGTAAAGGGATAG).

Chromatin immunoprecipitation (ChIP) assays
ChIP procedure followed is detailed in our earlier
publication [23]. Briefly, U87 cells were untreated or
treated with PBS or TNF-α were processed for ChIP
assay. Firstly, to crosslink protein and DNA, cells were
incubated with 1% formaldehyde for 10 minutes at 25°C.
2.5 M glycine for 5 minutes at room temperature (25°C)
was used to stop the crosslinking. Cells were washed
with cold PBS, lysed using lysis buffer. Chromatin was
sonicated (10 sec pulse 10 times, duty cycle 80, power
18) to generate sheared fragments falling in the range of
100bp to 1000bp. Crosslinked chromatin complex was
pre-cleared with protein G sepharose beads. p65 antibody
(10 μl; Catalog # 8242, Cell Signaling Technology,
U.S.A.) or control mouse antibody (IgG) was used to
immunoprecipitate the p65 bound DNA fragments.
Antibody-p65-DNA complex was captured using protein
G sepharose beads and washed. Protein-DNA complexes
reverse crosslinked and DNA was eluted. To assay the
p65 binding to IMP3 promoter, IMP3 promoter specific
primers (forward, 5′- GGCTGCGGTTCCTTTAG-3′
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Polysome analysis

constitute the TCGA research network can be found at
http://cancergenome.nih.gov/. The use of data sets from
GSE22866 is acknowledged. Dr. Sudhanshu Shukla
is acknowledged for discussions and his inputs. We
acknowledge Dr. Wakimoto H. (Massachusetts General
Hospital, Boston) for providing patient derived primary
GSCs. SB acknowledges CSIR, Government of India for
the research fellowship. KS acknowledges CSIR and DBT,
Government of India for research grant. Infrastructure
support by funding from DST-FIST, DBT grant-in-aid
and UGC (Centre for Advanced Studies in Molecular
Microbiology) to MCB is acknowledged. KS is a J. C.
Bose Fellow of the Department of Science and Technology.

The analysis was performed on U138 glioma cells
transfected with control siRNA or siRNA against IMP3.
Protocol was described earlier [17].

Histology and immunohistochemistry
GBM tumor sections were processed and stained
for p65, IMP3 and Sox-2 expression. 4mm sections were
collected on silane coated glass slides. Antigen retrieval
was performed by heat treatment in Tris-EDTA buffer
(10 mM Tris Base, 1 mM EDTA solution, 0.05% Tween
20, pH 9.0) at 850 W for 5 mins, 600 W for 10 mins and
450 W for 5 mins respectively. After initial processing,
the sections were incubated with the mentioned
antibodies. Incubation with secondary antibody (MACH1 Universal HRP-Polymer Detection kit) was followed.
3,3′-Diaminobenzidine (Sigma-Aldrich) was used as
chromogenic substrate. A semiquantitative grading scale
was used and the intensity of the immunoreactivity was
decided as follows: zero (0) if the staining was absent, 1+
for moderate staining and 2+ if it was strong. For IHC,
antibodies used were p65 (Catalog # 8242, Cell Signaling
Technology, U.S.A.), IMP3 (Catalog # ab109521, U.S.A.)
and SOX2 (Catalog # 3579, Cell Signaling Technology,
U.S.A.).
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